P-6755 Pazopanib, Hydrochloride Salt, >99%

New
  • Size
  • US $
  • £
  • ¥
  • 25 mg
  • 52
  • 44
  • 39
  • 5,800
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 71
  • 60
  • 54
  • 7,900
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 109
  • 93
  • 83
  • 12,100
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 168
  • 143
  • 128
  • 18,700
  • Add to Cart Qty:
  • In stock
  • 300 mg
  • 231
  • 197
  • 176
  • 25,700
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 327
  • 279
  • 249
  • 36,400
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 463
  • 395
  • 353
  • 51,500
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 794
  • 678
  • 606
  • 88,300
  • Add to Cart
  • Out of stock
  • 5 g
  • 1,390
  • 1,187
  • 1,061
  • 154,600
  • Add to Cart
  • Out of stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Click Here to see what Shipping and Handling Costs would be to Your Country
  • M.W. 473.98
  • C21H23N7O2S•HCl
  • [635702-64-6]

Certificate of Analysis

  • This research compound is the hydrochloride salt form of pazopanib; please see the other form of this product, Cat. No. [P-6706], Pazopanib, Free Base, for further technical information about both of these research compounds.
  • This pazopanib product is the hydrochloride salt, whose CAS number is given above. The CAS number of the free base form is 444731-52-6.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
537